Lou Gehrig's disease drug gets rare 2nd review by FDA advisers
Patients with the deadly neurological disease have rallied behind the drug from Amylyx Pharma and are lobbying the FDA for approval.
Stay updated with breaking news from Greg Canter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients with the deadly neurological disease have rallied behind the drug from Amylyx Pharma and are lobbying the FDA for approval.
A closely watched experimental drug for Lou Gehrig’s disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to...
A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig's disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group.
A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig's disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group.
Patients with the deadly neurological disease have rallied behind the drug from Amylyx Pharma and are lobbying the FDA for approval.